| Name | Aptamer Group |
|---|---|
| Epic | APTA |
| Isin | GB00BNRRP542 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.42p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £8.35 | Debt ratio | n/a |
| Shares in issue | 1,920.34 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -194.41 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.71 | 52-week high / low | 0.21p / 1.18p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Aptamer Group |
|---|---|
| Address | Windmill House, Innovation Way, Heslington, York, United Kingdom, YO10 5BR |
| Telephone | +44 (0)1904 567 790 |
| Website | http://aptamergroup.com/ |
| Director | Position |
|---|---|
| Mr Timothy J Sykes | Non-Executive Director |
| Mr Angela Hildreth | Senior Independent Non-Executive Director |
| Dr Ian David Gilham | Interim Chairman |
| Dr David Harry John Bunka | Chief Technical Officer |
| Dr John David Richards | Independent Non-Executive Director |
| Mr Rob Quinn | Interim CEO |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | 0.17 | 0.07 | 0.34 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.15 | 1.16 | 2.54 |
| Inventory / work in progress | 0.12 | 0.2 | 0.42 |
| Trade and other receivables | 0.44 | 0.68 | 1.87 |
| Cash and equivalents | 0.87 | 0.23 | 6.69 |
| Other current assets and asset held for resale | 0.19 | 0.47 | n/a |
| Total of all assets | 2.77 | 2.75 | 11.52 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 1.28 | 1.64 | 2.37 |
| Long term liabilities | 0.6 | 0.81 | 1.09 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.88 | 2.45 | 3.47 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 0.89 | 0.3 | 8.05 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.47 | 0.07 | 0.07 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -12.94 | -10.07 | -2.31 |
| Share premium account | 12.67 | 9.58 | 9.57 |
| Total equity | 0.89 | 0.3 | 8.05 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -3.08 | -8.16 | -2.58 |
| Pre-tax profit | -3.14 | -8.3 | -2.64 |